Korea Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s five largest COVID-19 vaccine manufacturing hubs by 2025. Here, we provide a rundown of some of the key companies involved…
USA Tatsuya Kaihara, head of US operations for Japanese eyecare specialist Santen, describes his excitement at bringing two new ophthalmic advancements to the US market, the similarities, differences, and synergies of Japanese and American innovation, and the challenges of building a unified corporate culture. This is a very exciting moment…
Global Charlotte Kremer is head of medical affairs for Astellas Pharma and serves as the president of the Medical Affairs Professional Society. At eyeforpharma Barcelona by Reuters Events 2020, a virtual conference held between March 31 and April 3, Kremer spoke on the evolving strategic role of medical affairs in driving…
Puerto Rico Jose Viera-Colon, Region Director Caribbean for Allergan, highlights the opportunities and obstacles related to leading the company’s commercial operations in Puerto Rico and countries like the Dominican Republic. He also gives insights in planned product launches in CNS and eyecare and explains Allergan’s approach to ensure product affordability for Puerto…
France Martine Claret of Horus Pharma – a family-owned ophthalmology pharmaceutical company established in 2003 and based in Nice – discusses the highly regulated and competitive ophthalmology market, the company’s remarkable recent growth, and the state of play for SMEs in France today. We as a flexible medium-sized company have…
Bristol-Meyers Squibb Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share…
Hong Kong Yvette Chu, general manager of CooperVision Hong Kong, shares the affiliate’s double-digit growth over the past three years, the importance of their relationships with the optometrists in Hong Kong, the value of their innovative and comprehensive portfolio of contact lenses, and her vision for the affiliate in the next few…
UK Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and establishing standards of care on a European level. I see technology as the enabler that creates new possibilities. Imaging…
UK Karen Osborn, CEO of the International Glaucoma Association, explains the role of the charity, detailing its threefold purpose of funding research, raising awareness and helping patients live with the disease. She speaks about possible care pathways of the future and international collaboration on research. We also collaborate on workshops…
UK Philip Lews Williams, managing director of the UK affiliate of French ophthalmology specialist Théa, describes the evolution of the company’s engagement in the UK and his strategy for taking on the big players in eyecare. Laboratoires Théa entered the UK for the first time back in 2007 via a joint…
Canada Dwight Gorham, president and CEO of Pillar5 Pharma, discusses the unique positioning of the CDMO in the multi-dose preservative free sterile ophthalmics space and stresses the importance of anticipating market trends in order to fuel expansion. Finally, he gives an insight into the importance of honing new skills and how…
Poland Krzysztof Kołodziejski, country manager of Santen Poland, discusses the strategy he put in place to modernize the business culture of the affiliate and how this has led to great success. Furthermore, he highlights the challenges being faced by innovative eyecare companies in Poland and the entire healthcare sector, as well…
See our Cookie Privacy Policy Here